SUPER Bugs are on the rise and the recent news story you cite is dead on point! The value of TTPH is rising for any large pharmaceutical player, as it would be a bolt on money machine! The unusual aspect to the area of antibiotics was stated by the CEO a month ago when he identified the area as being one in which the FDA required two passed Phase 3 Trials before that Agency would grant approval to a NDA. Indeed he stated "never has an antibiotic been approved on one P3 trial". See TTPH web Cite and transcripts. This revelation makes the price action of the stock upon news of the FDA decision confused, as it suggest that stockholders are not listening.
Certainly, more than a few shareholders will miss the significant escalation in stock price once the drama has passed! Given that NDA approval will occur upon a repeat performance of the spectacular performing cITI Trial, and, understanding that this important point will draw interest from large pharmaceutical players as they know it's science (repeatability lies as its core belief). Perhaps more importantly, the leadership team has also stated that food issues are believed to have interfered with the cUTI Phase 3. The current P1 is examining this issue and dosage for the oral pill formulation of eravacycline. The hope is to have data supporting an add on arm to the cUTI P3 trial (label extending trial). All together these developments support a strong position of inevitable outcome predictability, and accordingly, risk rationalization. That is the principle concern of an acquiring pharma. That suggest the possibility of a suitor arriving any day as the spoils go to the smart and brave.
